REG - Halma PLC - Acquisition

HalmaAnnouncement

18/11/2024 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20241118:nRSR5112Ma&default-theme=true

RNS Number : 5112M  Halma PLC  18 November 2024

Halma plc ('Halma' or the 'Group')

Acquisition

 

Halma, the global group of life-saving technology companies focused on growing
a safer, cleaner, healthier future for everyone, every day, today announces
that it has acquired Lamidey Noury Medical.

Founded in 1947 and headquartered close to Paris, Lamidey Noury manufactures
advanced electrosurgical and associated energy devices which are used in
minimally invasive urology, gynaecology, and general surgery. Its products are
sold to healthcare providers in over 60 countries.

The cash consideration for Lamidey Noury is €50m (approximately £42m), on a
cash- and debt-free basis, to be funded from Halma's existing facilities.

Lamidey Noury's unaudited revenue for the 12 months to October 2024 was
€13.6m (approximately £11.4m), with an EBIT margin above the upper end of
Halma's target range of 19-23%. Lamidey Noury will be a standalone company
within Halma's Healthcare Sector, led by its current management team.

Marc Ronchetti, Group Chief Executive of Halma, commented:

"Lamidey Noury is an exciting acquisition which will bring new minimally
invasive surgical product capabilities to our Healthcare Sector. Its advanced
products improve patient outcomes and the efficiency of healthcare providers
in treating the increasing incidence of urological and gynaecological disease.
It is adjacent to our existing presence in diagnosis and biopsy devices for
these diseases through Rovers Medical Devices and IZI Medical. We are
delighted to welcome Lamidey Noury to Halma and look forward to supporting its
development as it continues to scale its business globally."

Guillaume Noury, President of Lamidey Noury said:

"Joining Halma is an exciting opportunity for us. Leveraging Halma's
expertise, resources, and global reach will accelerate our growth and
innovation. We are confident in our ability to continue delivering
high-quality surgical tools to our customers worldwide, while providing new
opportunities for our employees and stakeholders. Together, we will continue
improving patient outcomes and driving excellence in healthcare."

 

For further information, please contact:

Halma plc

Marc Ronchetti, Group Chief Executive                    +44 (0)1494
721111

Steve Gunning, Group Chief Financial Officer

Charles King, Head of Investor Relations                  +44 (0)
7776 685948

Clayton Hirst, Director of Corporate Affairs             +44 (0) 7384
796 013

 

MHP

Oliver Hughes / Rachel Farrington / Ollie Hoare     +44 (0)20 3128 8100 /
+44 (0)7817 458 804 / halma@mhpgroup.com (mailto:halma@mhpgroup.com)

 

A copy of this announcement, together with other information about Halma, is
available at www.halma.com (http://www.halma.com/) .

 

About Halma

Halma is a global group of life-saving technology companies, focused on
growing a safer, cleaner, healthier future for everyone, every day. Its
purpose defines the three broad markets it operates in:

·      Health - Meeting the increasing demand for better healthcare as
chronic illness rises, driven by growing and ageing populations and lifestyle
changes.

·      Environment - Addressing the impacts of climate change, pollution
and waste, protecting life-critical resources and supporting scientific
research.

·      Safety - Protecting the safety of people and assets as
populations grow and the demand on infrastructure increases.

 

It employs over 8,000 people in more than 20 countries, with major operations
in the UK, Mainland Europe, the USA and Asia Pacific. Halma is listed
on the London Stock Exchange (LON: HLMA) and is a constituent of the FTSE 100
index.

Halma has been named as one of Britain's Most Admired Companies for the
past six years.

For more information www.halma.com (http://www.halma.com/)

 

ENDS

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  ACQBABRTMTABBBI